The New Lab Reality: 2025’s Most Important Shifts in Management, Technology, and Regulation

2025 was a pivotal and, at times, uncomfortable year for clinical laboratory management and laboratory information system (LIS) software. Workforce shortages, reimbursement pressure, AI and digital pathology, cybersecurity, and direct-to-consumer lab testing all moved from “future trend” to “immediate decision point” for lab leaders.

Here’s a recap of the major stories and themes that shaped 2025, and what they mean for laboratories and LIS system strategy going into 2026.

1. Workforce Crisis Finally Hits Washington’s Radar

Clinical labs and pathology practices have been sounding the alarm about staffing shortages for years. In 2025, that message finally crystallized into meaningful national and local action.

The Medical Laboratory Personnel Shortage Relief Act of 2025 was introduced in the U.S. House by Representatives Deborah Ross (D-NC) and Jen Kiggans (R-VA). The bipartisan bill would:

• Expand eligibility for the National Health Service Corps (NHSC) to include medical laboratory personnel.
• Create federal grants for accredited colleges and universities to train MLS and MLT students.
• Direct HHS to identify areas with critical lab workforce shortages and prioritize support there.

Read the Bill: H.R. 5444 - Medical Laboratory Personnel Shortage Relief Act of 2025

Advocacy groups and trade media such as Dark Daily highlighted the bill as a rare, targeted response to a profession where vacancy rates and retirements threaten basic access to diagnostic services.

At the same time, philanthropy stepped in. An anonymous donor gave the University of Washington over $50 million to cover tuition for senior-year clinical rotations for the school’s medical laboratory science students for the next 50 years, allowing the program to expand its class size from 70 to 100 students over time.

Learn More: An anonymous $50M gift will cover some tuition for medical lab students at the University of Washington

Taken together, 2025’s big workforce story is: the lab staffing crisis is no longer just an internal HR problem. It’s now a policy and funding priority, and labs should watch closely for new training partnerships, grant opportunities, and NHSC-related incentives that may help with recruitment and retention.

Industry Insights: Solving the Medical Laboratory Staffing Shortage with Advanced LIS Systems and Better Support

Editor’s Note: This story has been updated to reflect significant late-breaking legislative action affecting Medicare laboratory reimbursement.

On February 3, 2026, President Trump signed the Consolidated Appropriations Act, 2026 (H.R. 7148) into law. The legislation includes a one-year delay of pending Medicare Clinical Laboratory Fee Schedule (CLFS) price cuts mandated under the Protecting Access to Medicare Act (PAMA), providing short-term financial relief to the clinical laboratory industry.

Under the new law, the next round of Medicare payment reductions, previously expected to take effect in early 2026 and affecting nearly 800 tests with reductions of up to 15 percent, has been postponed until January 1, 2027.

Key updates include:

• Temporary Pause on CLFS Cuts: Medicare payment rates for clinical diagnostic laboratory tests will remain stable through December 31, 2026.
  
• Revised Private-Payer Data Collection: Instead of relying on older 2019 data, laboratories will now report private-payer data collected between January 1, 2025, and June 30, 2025.
  
• Updated Reporting Window: The reporting period for this data has been reset to May 1, 2026, through July 31, 2026.
  
• Extended Phase-In of Future Reductions: Additional CLFS cuts are now scheduled to be phased in during 2027, 2028, and 2029.

This congressional action represents another temporary intervention to delay PAMA-driven cuts and adjust the data-reporting methodology, an ongoing concern for laboratory advocates who argue that current CLFS pricing relies on outdated and unrepresentative market data.

Payment Pressure, PAMA, and the Fight to “Stop Lab Cuts” 

Looking back, 2025 was defined by mounting concern over Medicare reimbursement pressure tied to PAMA implementation.

Throughout the year:

• The Centers for Medicare and Medicaid Services continued to update the CLFS through quarterly revisions based on private-payer data, keeping laboratories on constant alert for pricing volatility.
• Professional organizations, including the American Society for Clinical Pathology, warned that CMS was preparing to reduce reimbursement for roughly one-third of the CLFS, nearly 800 tests, by as much as 15 percent absent legislative relief.
• The proposed RESULTS Act emerged as a longer-term reform effort, aiming to cap annual payment reductions at 5 percent once fully implemented, with strong advocacy from the American Clinical Laboratory Association.
• Earlier reform initiatives, including the Saving Access to Laboratory Services Act, continued to influence policy discussions around how private-market data is collected and applied to CLFS pricing.

What This Means for Laboratories

Even with the 2026 delay now in place, reimbursement uncertainty remains a structural reality. For laboratory leaders, LIS system administrators, and laboratory revenue cycle management teams, the takeaway is clear: pricing volatility is not disappearing; it is merely deferred.

In response, many laboratories are doubling down on:

• Stronger test utilization management strategies.
• Tightly integrated laboratory information system and lab revenue cycle management workflows to reduce denials and write-offs.
• Advanced analytics to model the financial impact of future CLFS reductions on specific test menus and service lines.

3. AI and Digital Pathology Move from Pilot to Production

If 2023–2024 were about early adoption, 2025 was the year AI-enabled digital pathology started to look mainstream.

Several storylines stood out:

• The U.S. Food and Drug Administration (FDA) issued both draft and final guidance on AI-enabled medical devices, covering lifecycle expectations and post-market oversight. It also granted Breakthrough Device designation to technologies that offer more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions.
• Academic reviews emphasized how whole slide imaging (WSI) and AI are reshaping pathology through remote collaboration, algorithmic decision support, and more standardized interpretations.
• Reports on the first AI-based tools cleared to support cancer pathology reinforced that regulators are increasingly comfortable with algorithmic assistance when evidence is strong and workflows are well-defined. 

For LIS system buyers, digital pathology is no longer just about image storage. Modern LIS and pathology platforms now need to:

• Handle DICOM-based whole slide images and image-linked metadata.
• Integrate with AI algorithms in a way that is auditable and compliant.
• Support hybrid workflows with pathologists fluidly operating between glass slides and digital cases.

In short, the advanced LIS system is becoming the orchestration layer for human-plus-AI pathology.

Case Study: OnePath - Transforming Pathology Lab Management Through Digital Innovation

4. Laboratory Information Systems and Lab IT: From Systems of Record to Systems of Action

On the laboratory information systems side, 2025 was defined less by single “headline products” and more by architectural shifts.

AI-First and Cloud-Native LIS

Black Book Research’s Global State of Healthcare Laboratory IT report highlighted how labs in Europe and North America are moving from compliance-driven modernization to AI-first architectures, cloud deployment, and advanced interoperability over the next decade.

Market analysts estimate the global lab information system market at roughly $891 million in 2024, projected to grow to around $1.3 billion by 2032 at a 5–6 percent CAGR.

Meanwhile, buyer guides ranking the best laboratory information system companies in 2025 underscored just how crowded and stratified the medical LIS software market has become, from large enterprise EHR-tethered solutions to specialized best-of-breed platforms. 

Industry commentary increasingly describes modern LIS system platforms as shifting from “systems of record” to “systems of action” - active hubs that trigger alerts, drive automation, and coordinate workflows across electronic health records, laboratory billing, outreach portals, digital pathology solutions, and more.

Industry Insights: From System of Record to System of Action - The Next Evolution of Laboratory Information Systems

TEFCA and Nationwide Interoperability

On the policy side, TEFCA (Trusted Exchange Framework and Common Agreement) moved from concept to operational reality:

• TEFCA went live in late 2023; by 2025, multiple Qualified Health Information Networks (QHINs) were actively exchanging data nationwide.
• Recent implementation guides stress that TEFCA offers “one on-ramp” instead of dozens of custom interfaces, but also raise the bar around consent, audit, identity management, and security. 

Learn More: A Nationwide Network-of-Networks for Health Information Exchange

For clinical labs and pathology groups, this means LIS system roadmaps now have to account for:

• QHIN connectivity and TEFCA-aligned workflows for result delivery, public health reporting, and individual access.
• More robust APIs and FHIR-based interfaces that let lab data move fluidly through national exchange networks.
• Governance and logging that can withstand increasing regulatory scrutiny around information blocking and patient access.

Discover More: LigoLab Delivers the LIS System Interoperability Needed to Transform Medical Laboratories into Thriving Businesses

5. Cybersecurity and Ransomware: From IT Risk to Patient Safety Crisis

Cybersecurity was one of the most sobering stories in healthcare overall, and diagnostic labs were squarely in the crosshairs.

Some key 2025 data points:

• Across the first nine months of 2025, there were 293 ransomware attacks on hospitals, clinics, and other direct care providers, plus another 130 attacks on healthcare businesses such as lab vendors, lab revenue cycle management companies, and tech providers. Attacks on healthcare businesses rose roughly 30 percent compared to the year before.
• Pathology and lab organizations were hit directly: WPM Pathology Laboratory in Kansas and Pacific Biolabs in California both reported ransomware incidents involving network intrusion and alleged data theft. 

Learn More: Ransomware Gangs Attack Clinical and Pathology Laboratories

These stories mark an inflection point: ransomware is now explicitly linked to patient harm and mortality.

For LIS lab management, cybersecurity has become a core operational competency, implying:

• More rigorous vendor due diligence and shared-responsibility models for cloud systems.
• Zero-trust architectures, network segmentation for analyzer connections, and stronger identity and access management.
• Comprehensive disaster recovery plans that assume temporary loss of LIS/RCM/EHR connectivity and define manual fallback procedures.

Discover More: LigoLab’s Enhanced Cybersecurity Solutions Give Customers Added Protection and Peace of Mind

6. Direct-to-Consumer Labs and Decentralized Testing Go Mainstream

Another big 2025 storyline: lab testing “escaped the four walls” even further.

Several signals stood out:

• The direct-to-consumer lab testing market reached an estimated $3.62 billion in 2025, with projections nearing $6 billion by 2030.
• Analyses noted that by 2025, DTC lab testing had become “mainstream”, with an ecosystem of startups, telehealth providers, and retail health players offering everything from wellness panels to chronic disease monitoring.

Discover More: Direct-to-Consumer Lab Testing - Market Analysis & Impact on Healthcare

This trend affects more than consumer-facing brands; it has direct implications for LIS system platforms and clinical/pathology lab management:

• Outreach labs need LIS software platforms that can support multi-channel ordering (providers, retail, telehealth, and direct consumer), each with different ordering, consent, and billing rules.
• Laboratory revenue cycle management systems must handle more complex payer mixes and price-transparency expectations.
• Quality, accreditation, and medical supervision requirements must be maintained even when orders originate from consumer apps rather than traditional clinics.

White Paper: How Labs Can Achieve Financial Stability During Turbulent Times

What It All Means for Lab Leaders and LIS System Strategy in 2026

Pulling these threads together, 2025’s major stories point toward a few clear imperatives for laboratory workflow management and LIS system planning:

• Plan for structural workforce support, not just local hiring fixes. Watch for NHSC eligibility, grants, and academic partnerships that can stabilize recruiting pipelines. Align your LIS software training and onboarding processes to make new graduates productive faster.
• Treat reimbursement risk as a design input, not an afterthought. With PAMA and impending CLFS cuts, financial resilience depends on data visibility. Integrated LIS–RCM workflows, robust rule engines, and denial-prevention analytics are no longer “nice to have.”
• Assume AI and digital pathology will touch your workflows. Even if you’re not fully digital yet, your next LIS or anatomic pathology software decision should anticipate DICOM imaging, AI integration, and remote collaboration features. Regulatory guidance is now clearer, which reduces adoption risk.
• Make interoperability and TEFCA alignment part of your LIS system RFP. As QHINs mature, labs that can plug into national networks will be better positioned for value-based care, public health reporting, and patient-centric services.
• Elevate cybersecurity to the same level as quality and safety. Ransomware is now a patient safety issue. Your LIS system roadmap should be deeply integrated with an enterprise security strategy, with clear contingency plans for diagnostic continuity during outages.
• Prepare for multi-front lab outreach and direct-to-consumer lab testing partnerships. Whether you’re running your own DTC brand, partnering with telehealth players, or serving retail clinics, your LIS system needs to support flexible ordering channels, identity management, and consumer-grade reporting experiences.

2025 didn’t bring a single “moonshot” moment for lab informatics, but it did deliver something more consequential: convergence. Workforce policy, payment reform, AI, interoperability, cybersecurity, and consumerization all collided in ways that make LIS systems and lab IT strategy a board-level discussion. For labs that embrace this convergence and invest accordingly, 2026 and beyond will be less about survival and more about shaping the next generation of diagnostic care.

See How LigoLab Is Shaping the Future of Laboratory Operations

2025 was a landmark year for LigoLab, marked by breakthrough platform enhancements, major digital pathology partnerships, new AI-driven automation capabilities, and record customer growth across every diagnostic discipline.

And we’re just getting started.

In 2026, LigoLab will continue raising the bar with even more powerful laboratory information system software solutions designed to help labs scale, stay competitive, and thrive in an increasingly complex healthcare landscape.

Ready to experience what the next generation of LIS & RCM innovation looks like?

Connect with our team today and see how LigoLab can help your laboratory unlock a more efficient, profitable, and future-ready operation.

Act Now: Speak with a Product Specialist Today!

‍